TTrialPathMatch Me to Trials
← Back to trials
RecruitingTriple Negative Breast CancerRenal Cell CancerHigh Grade Ovarian Serous Adenocarcinoma

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab with or without Ipilimumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 Moditope will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.

Sponsor: Scancell Ltd

You may qualify if…

  • ✓ 1. Patient either has one of the following histologically or cytologically confirmed advanced cancers not amenable to curative intent surgical resection:
  • ✓ TNBC
  • ✓ SCCHN (oral cavity, oropharynx, hypopharynx, or larynx)
  • ✓ HGSOC including fallopian tube and primary peritoneal cancers
  • ✓ RCC Or the patient has histologically or cytologically confirmed SCCHN scheduled to have curative intent surgical resection.
  • ✓ 2. Patient must meet one of the following specific criteria for prior treatment of the relevant tumour type:
  • ✓ TNBC:
  • ✓ patient has received available standard therapy for advanced disease (Modi-1ev/Modi-1eKv monotherapy cohort only).

You may not qualify if…

  • ✕ 1. Patient has symptomatic central nervous system metastases or carcinomatous meningitis.
  • ✕ 2. Patient is taking any systemic steroid therapy (exceeding 10 mg/day of prednisolone or equivalent) or is on any other form of immune suppressant medication within 2 weeks prior to the first dose of IMP. Physiological doses of systemic steroids such as those for the management of adrenal insufficiency, topical and inhaled steroids, such as those for the management of asthma, and patients with hypothyroidism stable on hormone replacement, are permitted.
  • ✕ 3. Patient has a history of malignancy other than the disease under study within 2 years prior to Screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 2-year overall survival rate \>90%), such as adequately treated carcinoma-in-situ of the breast or the cervix, melanoma-in-situ, non-melanoma skin carcinoma, superficial bladder cancer, prostate cancer with Gleason grade ≤6 and prostate specific antigen within normal range or stage I endometrial cancer.
  • ✕ 4. Patient is pregnant, lactating, or is expecting to conceive/father children within the duration of the study.
  • ✕ 5. Patient has a concurrent illness which would preclude study conduct and assessment, including, but not limited to, uncontrolled medical conditions, uncontrolled and active infection (considered opportunistic, life threatening, or clinically significant), uncontrolled risk of bleeding, uncontrolled diabetes mellitus, pulmonary disease (including obstructive pulmonary disease and pulmonary fibrosis), alcoholic liver disease, or primary biliary cirrhosis.
  • ✕ 6. Patient has New York Heart Association (NYHA) class III or IV heart disease, myocardial infarction or stroke within previous 6 months, a history of significant cardiac abnormality and/or significant abnormal baseline ECG readout, active ischaemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy, uncontrolled hypertension, significant cerebrovascular disease, or congestive heart failure.
  • ✕ 7. Patient has anti-CCP antibody levels classified as equivocal or positive according to NHS guidelines, i.e., ≥ the ULN, or has an active autoimmune disease that may impact on the study treatment in the opinion of the Investigator.
  • ✕ 8. Patient has received a live vaccine within 28 days, or an influenza vaccine within 14 days prior to the first dose of IMP. The timing of any other vaccines should be assessed on a case-by-case basis by the Investigator prior to study enrolment.

Source: ClinicalTrials.gov · NCT05329532 · last updated 2025-09-17